Page 8 - Celcuity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib

Maria yonkoskiVicky hahneBrian sullivanExchange commission onCelcuity incAntonio breast cancer symposiumChief executive officerBreakthrough therapyRisk factorsAnnual reportExchange commission

Celcuity Inc (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC – Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 366,900 shares, a drop of 10.6% from the October 31st total of 410,300 shares. Based on an average trading volume of 61,300 shares, the […]

United statesCelcuity company profileTradition wealth managementBarclays plcCelcuity incNeedham companyAmerica corpGet free reportWealth managementCalifornia state teachers retirement systemCelcuity dailyNasdaq celc

Celcuity to Participate in the 6th Annual Evercore ISI

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted.

United statesBrian sullivanMaria yonkoskiVicky hahneCelcuity incAnnual evercoreChief executive officerNasdaq celcElcuity incBreast cancerProstate cancerViktoria 1

Celcuity (NASDAQ:CELC) Posts Earnings Results, Misses Expectations By $0 09 EPS

Celcuity (NASDAQ:CELC) Posts Earnings Results, Misses Expectations By $0 09 EPS
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United kingdom generalUnited kingdomUnited statesMorgan stanleyBlackrock incCelcuity incNeedham companyGet free reportMarketwatch earningsFinancial advisorsState street corpStreet corpCelcuity daily

Research Analysts Updated EPS Estimates for November 13th (AADI, ANNX, ARMK, CELC, CRK, ENZ, FUN, MDB, MERC, NSIT)

Research Analysts’ updated eps estimates for Monday, November 13th: Aadi Bioscience (NASDAQ:AADI) had its price target reduced by HC Wainwright from $45.00 to $36.00. HC Wainwright currently has a buy rating on the stock. Annexon (NASDAQ:ANNX) had its price target trimmed by Needham & Company LLC from $24.00 to $16.00. They currently have a buy […]

Replimune groupNeedham companyHealth servicesInsight enterprisesSeritage growth propertiesResearch analystMercer internationalAadi bioscience incNews ratings for aadi bioscience inc dailyTruist financial coCedar fairSix flags entertainmentGrowth propertiesTigress financialTruist financialAadi bioscience inc daily